Literature DB >> 846623

Androgens in the anaemia of chronic renal failure.

B von Hartitzsch, D N Kerr, G Morley, B Marks.   

Abstract

Plasma levels of testosterone-like substances (TLS) were depressed in seven patients with chronic renal failure. Intramuscular testosterone (as Sustanon 250 once a week) elevated plasma TLS levels to above normal throughout the week with an initial high peak. Sublingual testosterone produced a high but brief peak in TLS. Results were similar in renal failure patients and normal controls. A controlled trial of weekly Sustanon 250 in 24 regular dialysis patients produced a significant increase in haemoglobin from 6.8 to 8.2 g/dl. Side effects were mainly mild and acceptable but one patient developed priapism and another a large haematoma. The discriminate use of androgens is recommended for anaemic male patients on regular haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 846623     DOI: 10.1159/000180761

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

Review 1.  Effects of androgen replacement on metabolism and physical performances in male hypogonadism.

Authors:  M Zitzmann; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

2.  Androgens in the anaemia of chronic renal failure.

Authors: 
Journal:  Br Med J       Date:  1977-08-13

3.  Androgen therapy for anemia in renal failure.

Authors:  S I Ryabov; G D Shostka; T V Vinogradova
Journal:  Int Urol Nephrol       Date:  1980       Impact factor: 2.370

4.  Erythropoietin producing cells for potential cell therapy.

Authors:  Tamer Aboushwareb; Fernanda Egydio; Lauren Straker; Kenneth Gyabaah; Anthony Atala; James J Yoo
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

5.  Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin.

Authors:  Myeung Su Lee; Seon Ho Ahn; Ju Hung Song
Journal:  Korean J Intern Med       Date:  2002-09       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.